

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Decision Cover Letter

Decision of the licensing authority to:

accept change(s) to the agreed paediatric investigation plan and to the deferral.

MHRA-101513-PIP01-24-M02

Scope of the Application

Active Substance(s)

ERTUGLIFLOZIN L-PYROGLUTAMIC ACID

Condition(s)

Treatment of type 2 diabetes mellitus

Pharmaceutical Form(s)

Film-coated tablet

Route(s) of Administration

ORAL USE

Name / Corporate name of the PIP applicant

Merck Sharp & Dohme (UK) Limited

Basis for the Decision

Pursuant to the Human Medicines Regulations 2012, Merck Sharp & Dohme (UK) Limited submitted to the licensing authority on 24/12/2025 11:35 GMT an application for a Modification

The procedure started on 05/01/2026 14:53 GMT

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to accept change(s) to the agreed paediatric investigation plan and to the deferral.

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Final Decision Letter

MHRA-101513-PIP01-24-M02

Of 05/03/2026 07:27 GMT

On the adopted decision for ERTUGLIFLOZIN L-PYROGLUTAMIC ACID (MHRA-101513-PIP01-24-M02) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Agreement on modification of a paediatric investigation plan.

This decision applies to a Modification for ERTUGLIFLOZIN L-PYROGLUTAMIC ACID, Film-coated tablet , ORAL USE .

This decision is addressed to Merck Sharp & Dohme (UK) Limited, 120 Moorgate, London, UNITED KINGDOM, EC2M 6UR

ANNEX I

1. Waiver

1.1 Condition:

Treatment of type 2 diabetes mellitus The waiver applies / applied to: Paediatric Subset(s): The paediatric population from birth to less than 10 years of age. Pharmaceutical form(s): Film-coated tablet Route(s) of administration: ORAL USE Reason for granting waiver: On the grounds the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s)

2. Paediatric Investigation Plan:

2.1 Condition(s):

Treatment of type 2 diabetes mellitus

2.2 Indication(s) targeted by the PIP:

Treatment of type 2 diabetes mellitus

2.3 Subset(s) of the paediatric population concerned by the paediatric development:

The paediatric population from 10 years to less than 18 years of age.

2.4 Pharmaceutical Form(s):

Film-coated tablet

2.5 Studies:

Study Type	Number of Studies	Study Description
Quality Measures	0	Not applicable.
Non-Clinical Studies	1	Study 1 Juvenile toxicity study in the rat to further evaluate the safety profile of ertugliflozin on the developing organism.
Clinical Studies	1	Study 2 Randomised, double-blind, placebo-controlled trial to evaluate the safety and efficacy of two doses of ertugliflozin in paediatric patients from 10 years to less than 18 years of age with type 2 diabetes mellitus and inadequate glycaemic control on metformin therapy, ± insulin.
Extrapolation, Modeling & Simulation Studies	1	Study 3 Population PK modelling study to evaluate the appropriate dose of ertugliflozin in the treatment of type 2 diabetes mellitus in children from 10 to less than 18 years of age.
Other Studies	0	Not applicable.
Other Measures	0	Not applicable.

3. Follow-up, completion and deferral of a PIP:

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	31/03/2026
Deferral of one or more studies contained in the paediatric investigation plan:	Yes

